Last reviewed · How we verify
Nippon Shinyaku Co., Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cytarabine | Cytarabine | marketed | Antimetabolite | DNA polymerase | Oncology | 1969-01-01 |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- Centre Oscar Lambret · 1 shared drug class
- EMD Serono Research & Development Institute, Inc. · 1 shared drug class
- GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
- Grupo Espanol Multidisciplinario del Cancer Digestivo · 1 shared drug class
- Hoffmann-La Roche · 1 shared drug class
- Asan Medical Center · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Nippon Shinyaku Co., Ltd.:
- Nippon Shinyaku Co., Ltd. pipeline updates — RSS
- Nippon Shinyaku Co., Ltd. pipeline updates — Atom
- Nippon Shinyaku Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Nippon Shinyaku Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nippon-shinyaku-co-ltd. Accessed 2026-05-16.